Can methotrexate cause infertility? Methotrexate does not cause permanent infertility in the great majority of men and women. It transiently suppresses sperm production and can disrupt ovulation, but it does not destroy the ovarian egg reserve, and sperm production recovers after stopping the drug. The real fertility risks come from indirect pathways: age-related delay during long treatment courses, folate depletion, and — in men — a possible but unproven link to testicular toxicity at high cumulative doses. Fertility generally returns within 3 to 6 months of stopping methotrexate in women and 2 to 3 months in men.
How methotrexate reaches the reproductive organs
Methotrexate is a folate antagonist. It inhibits dihydrofolate reductase, the enzyme that regenerates tetrahydrofolate, the one-carbon carrier cells need to synthesize DNA building blocks (thymidine and purines). Rapidly dividing cells are hit hardest: bone marrow, gut lining, hair follicles — and the germ cells inside the testes and ovaries.
In the testis, spermatogonia divide continuously. That continuous division makes them vulnerable during exposure but also the reason sperm production rebounds once the drug clears. The blood-testis barrier limits how much methotrexate reaches mature sperm, which is one reason semen quality recovers rather than collapses permanently in most patients.
In the ovary, the situation is different. A woman is born with a fixed pool of oocytes that do not divide. Methotrexate therefore cannot kill eggs the way it kills dividing cells; instead, the concern is follicular function and hormonal signaling. Methotrexate exposure has been associated with elevated follicle-stimulating hormone (FSH) in some small studies, suggesting temporary ovarian suppression rather than depletion.
In plain terms: the drug interferes with cells that multiply fast, and it also nudges hormone signaling. Neither effect has been shown to permanently erase the ability to conceive in typical rheumatology or dermatology doses.
What the numbers actually say: a quantified comparison
The table below compares methotrexate's documented reproductive effects across the two sexes using the best available data. Dose ranges reflect standard low-dose regimens used for rheumatoid arthritis and psoriasis (7.5 to 25 mg per week) versus high-dose oncology regimens (grams per square meter).
| Parameter | Women | Men |
|---|---|---|
| Primary mechanism of concern | Ovulation disruption, folate depletion | Impaired spermatogenesis, DNA fragmentation |
| Typical low-dose exposure effect | Ovulatory dysfunction in a minority; cycles often continue | Sperm count reduction reported in some cohorts; often reversible |
| Time to recovery after stopping | 3 to 6 months (ovarian cycle re-establishment) | 2 to 3 months (one full spermatogenic cycle plus margin) |
| Evidence for permanent sterility at low dose | None established | None established |
| High-dose oncology exposure | Ovarian failure risk rises, dose-dependent | Azoospermia reported; recovery variable |
| Guideline position on conception timing | Stop 3 months before attempting conception | Stop 3 months before conception (semen quality) |
The 3-month figure appears repeatedly in rheumatology guidance because a full spermatogenic cycle takes roughly 74 days, and follicular recruitment and maturation add weeks. Per the 2020 American College of Rheumatology reproductive health guidelines, both men and women are advised to discontinue methotrexate at least 3 months before attempting conception. That number is the practical floor, not a guarantee.
In men, one frequently cited cohort found that sperm concentration and motility improved after methotrexate withdrawal, with most parameters returning toward baseline within one spermatogenic cycle. In women, studies of low-dose methotrexate in inflammatory arthritis have generally not shown reduced ovarian reserve markers compared with controls, though sample sizes are small.
Can methotrexate cause infertility in women? The ovarian reserve question
The central female question is whether methotrexate accelerates the loss of the ovarian follicle pool — the reserve that determines reproductive lifespan. The evidence so far says no at standard doses, with caveats.
Anti-Müllerian hormone (AMH) is the best available marker of ovarian reserve. Studies of women with rheumatoid arthritis on methotrexate have mostly found AMH levels comparable to age-matched controls. A 2019 observational study reported no significant decline in AMH attributable to methotrexate exposure after adjusting for age and disease activity. Disease activity itself, and the systemic inflammation of autoimmune disease, may suppress ovarian function independently of the drug.
The exception is high-dose methotrexate used in oncology, particularly in young women treated for leukemia or lymphoma. At cumulative doses in the grams-per-square-meter range, ovarian failure becomes a real risk, and the probability rises with age at exposure. A woman treated at 15 has a lower risk of premature ovarian insufficiency than one treated at 35, because she starts with more follicles.
There is also an indirect pathway that matters more than direct toxicity for many women: time. Methotrexate is often started in the late twenties or early thirties and continued for years while disease is controlled. If a woman defers pregnancy during that window, her age — not the drug — becomes the dominant fertility variable. A 32-year-old who waits five years on treatment is 37 when she stops, and age-related decline outpaces anything methotrexate plausibly does.
Can methotrexate cause infertility in men? Sperm production and DNA integrity
Male fertility under methotrexate has been studied less rigorously than female fertility, and the findings are mixed. Several small studies report reductions in sperm count, motility, or normal morphology during treatment. Others find no meaningful difference from controls. The heterogeneity likely reflects differences in dose, duration, disease, and the fact that semen analysis itself varies substantially between samples.
A more subtle concern is sperm DNA fragmentation. Methotrexate interferes with folate metabolism, and folate is essential for the one-carbon reactions that build and repair DNA. Some researchers have hypothesized that folate antagonism could increase DNA damage in sperm, which matters for pregnancy outcomes even when counts look normal. This remains a hypothesis rather than an established clinical effect; direct evidence in men on low-dose methotrexate is limited.
What is reasonably established is reversibility. Because spermatogenesis restarts from spermatogonial stem cells that survive treatment, most men recover sperm production after stopping. The practical recommendation — stop 3 months before attempting conception — is designed to allow a full cycle of new sperm to replace any exposed cells.
The time course: what happens and when
Fertility effects of methotrexate follow a predictable timeline tied to cell turnover and drug clearance. The table below maps the expected sequence for a patient stopping low-dose methotrexate before conception.
| Time point | What is happening | Clinical implication |
|---|---|---|
| Week 0 | Last methotrexate dose | Contraception still required |
| Weeks 1–4 | Drug clears; folate stores begin to recover | Start or continue folic acid supplementation |
| Months 1–2 | Spermatogenesis restarts; ovarian cycles may normalize | Men may see early semen improvement |
| Months 2–3 | New sperm cohort matures; ovulation re-established | Fertility attempts may begin at 3 months per guidelines |
| Months 3–6 | Full recovery expected in most | Women with irregular cycles warrant evaluation |
| Beyond 6 months | Persistent abnormality suggests other causes | Investigate independently of methotrexate |
The timeline is a planning tool, not a stopwatch. Some men show improved semen parameters by 8 to 12 weeks; others take 4 to 6 months. Women whose cycles were irregular before treatment may not regularize simply because the drug stopped.
Common misconceptions and a professional caveat
The most common misconception is that methotrexate is a "chemotherapy drug" and therefore sterilizes everyone who takes it. That framing conflates dose. Oncology methotrexate is given in grams; rheumatology and dermatology methotrexate is given in milligrams — a thousand-fold difference. Toxicity is dose-dependent, and the reproductive risk profile at 15 mg weekly is not the profile at 3 g per square meter.
A second misconception is that once methotrexate is stopped, fertility is instantly restored. It is not. The 3-month window exists because cell turnover takes time, and a couple who conceive immediately after stopping may do so with sperm or eggs exposed to the drug. That is why contraception during treatment and for 3 months after is standard advice.
A third misconception concerns folate. Many patients assume that because methotrexate depletes folate, taking a prenatal vitamin cancels the effect. It does not cancel the drug's mechanism, though adequate folate is still recommended for anyone planning pregnancy. Folate supplementation supports fetal neural tube development; it does not neutralize methotrexate's antifolate action.
The professional caveat: most fertility data on methotrexate come from observational studies in autoimmune disease populations, often with small samples and confounding by disease activity, age, and concomitant medications. Absence of demonstrated harm is not the same as proven safety, and the confidence intervals around these estimates are wide.
Red flags that warrant a fertility evaluation
Not every fertility problem in a patient on methotrexate is caused by methotrexate. The following warrant independent evaluation rather than watchful waiting:
- No return of regular menstrual cycles within 6 months of stopping the drug
- Semen analysis still abnormal 6 months after discontinuation
- Known prior exposure to high-dose methotrexate or other gonadotoxic therapy
- Age over 35 with more than 6 months of unprotected intercourse without conception
- Symptoms of premature ovarian insufficiency: hot flashes, amenorrhea, elevated FSH before age 40
- A partner with known fertility factors, since male and female factors combine
What to actually do: practical steps for patients and couples
Plan the pause deliberately. If pregnancy is on the horizon, discuss a preconception timeline with the prescribing clinician at least 6 months ahead, not after a positive test. The 3-month discontinuation window should be built into the plan.
Use effective contraception during treatment and for 3 months after. Methotrexate is also a known teratogen — it can cause birth defects — so the interval protects a potential pregnancy as well as allowing reproductive recovery.
Take folic acid as directed. Standard supplementation is 1 mg daily for most patients on low-dose methotrexate; women planning pregnancy typically take 400 to 800 micrograms daily, and higher doses may be advised after discussion.
For men, request a semen analysis if there is any concern, ideally at baseline and again 3 months after stopping. For women, AMH testing is optional and most useful when there is a specific question about ovarian reserve, not as a routine screen.
Do not stop methotrexate abruptly without a plan. Uncontrolled disease flares carry their own fertility and pregnancy risks, and the balance between disease control and reproductive planning should be individualized.
Limits of the evidence and what remains unknown
The honest position is that methotrexate's fertility effects are better characterized for women than for men, and better at low dose than at high dose. Long-term prospective data on pregnancy outcomes after paternal methotrexate exposure are sparse. Sperm DNA fragmentation studies in men on low-dose methotrexate are few and small.
What is not in doubt is the mechanism: methotrexate interferes with folate-dependent cell division, and reproductive cells depend on that division. What remains uncertain is how much that interference translates into clinically meaningful fertility loss at the doses most patients actually take. For now, the evidence supports reassurance with a structured pause, not alarm.